Schmidt C, Wiedmann F, Zhou XB, Heijman J, Voigt N, Ratte A, Lang S, Kallenberger SM, Campana C, Weymann A, De Simone R, Szabo G, Ruhparwar A, Kallenbach K, Karck M, Ehrlich JR, Baczkó I, Borggrefe M, Ravens U, Dobrev D, Katus HA, Thomas D. (2017) Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy. Eur Heart J. 47:1535-154.

Schmidt C, Wiedmann F, Voigt N, Zhou XB, Heijman J, Lang S, Albert V, Kallenberger S, Ruhparwar A, Szabó G, Kallenbach K, Karck M, Borggrefe M, Biliczki P, Ehrlich JR, Baczkó I, Lugenbiel P, Schweizer PA, Donner BC, Katus HA, Dobrev D, Thomas D. (2016) Response to Letter Regarding Article, "Upregulation of K2P3.1 K+ Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation". Circulation 133: 440-1.

Schmidt C, Wiedmann F, Voigt N, Zhou XB, Heijman J, Lang S, Albert V, Kallenberger S, Ruhparwar A, Szabó G, Kallenbach K, Karck M, Borggrefe M, Biliczki P, Ehrlich JR, Baczkó I, Lugenbiel P, Schweizer PA, Donner BC, Katus HA, Dobrev D, Thomas D. (2015) Upregulation of K2P3.1 K+ Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation. Circulation 132: 82-92.

Schmidt C, Wiedmann F, Kallenberg S, Ratte A,  Schulte J, Scholz B, Müller FU, Voigt N, Zafeirioue M-P, Ehrlich JR,  Tochtermann U, Veres G, Ruhparwar A, Karck M, Katus HA, Thomas D (2017) Stretch-activated two-pore-domain (K2P) potassium channels in the heart: focus on atrial fibrillation and heart failure. Prog Biophys Mol Bio; 130:233-243.

Rinné S, Kiper AK, Schmidt C, Ortiz-Bonnin B, Zwiener S, Seebohm G, Decher N. (2017) Stress-Kinase Regulation of TASK-1 and TASK-3. Cell Physiol Biochem. 44(3):1024-1037

Schmidt C, Wiedmann F, Langer C, Tristram F, Anand P, Wenzel W, Lugenbiel P, Schweizer P, Katus HA, Thomas D (2014) Cloning, functional characterization and remodeling of K2P3.1 (TASK-1) potassium channels in a porcine model of atrial fibrillation and heart failure. Heart Rhythm 11: 1798-805.

Kallenberger S, Schmid C, Wiedmann F, Mereles D, Katus HA, Thomas D, Schmidt C. (2016) A Simple, Non-Invasive Score to Predict Paroxysmal Atrial Fibrillation. PLoS One 11: e0163621.

Wiedmann F, Schmidt C, Lugenbiel P, Staudacher I, Rahm AK, Seyler C, Schweizer PA, Katus HA, Thomas D. (2016) Therapeutic targeting of two-pore-domain potassium (K2P) channels in the cardiovascular system. Clin Sci (Lond) 130: 643-50.

Schmidt C, Wiedmann F, Gaubatz A, Ratte A, Katus H, Thomas D (2018) New targets for old drugs: cardiac glycosides inhibit atrial-specific K2P3.1 (TASK-1) channels. Journal of Pharmacology and Experimental Therapeutics. in press

Schmidt C, Peyronnet R. (2018) Voltage-gated and stretch-activated potassium channels in the human heart : Pathophysiological and clinical significance. Herzschrittmacherther Elektrophysiol. 29(1):36-42.

El-Battrawy I, Zhao Z, Lan H, Li X, Yücel G, Lang S, Sattler K, Schünemann JD, Zimmermann WH, Cyganek L, Utikal J, Wieland T, Bieback K, Bauer R, Ratte A, Pribe-Wolferts R, Rapti K, Nowak D, Wittig J, Thomas D, Most P, Katus HA, Ravens U, Schmidt C, Borggrefe M, Zhou XB, Müller OJ, Akin I. (2018) Ion Channel Dysfunctions in Dilated Cardiomyopathy in Limb-Girdle Muscular Dystrophy. Circ Genom Precis Med. 11(3):e001893

Glasscock E, Voigt N, McCauley MD, Sun Q, Li N, Chiang DY, Zhou XB, Molina CE, Thomas D, Schmidt C, Skapura DG, Noebels JL, Dobrev D, Wehrens XH. (2015) Expression and function of Kv1.1 potassium channels in human atria from patients with atrial fibrillation. Basic Res Cardiol. 110(5):505

Schmidt C, Wiedmann F, Schweizer PA, Katus HA, Thomas D (2014) Inhibition of cardiac two-pore-domain K+(K2P) channels – an emerging antiarrhythmic concept. Eur J Pharmacol 738: 250-5.

Schmidt C, Wiedmann F, Tristram F, Anand P, Wenzel W, Lugenbiel P, Schweizer P, Katus HA, Thomas D (2013) Cardiac expression and atrial fibrillation-associated remodeling of K2P2.1 (TREK-1) K+ channels in a porcine model. Life sci S0024-3205: 753-4.

Schmidt C*, Wiedmann F*, Schweizer PA, Becker R, Katus HA, Thomas D (2013) Class I antiarrhythmic drugs target cardiac two-pore domain potassium (K2P) channels. Eur J Pharmacol 721: 237-48.

Li J, Seyler C, Wiedmann F, Schmidt C, Schweizer PA, Becker R, Katus HA, Thomas D. (2013) Anti-KCNQ1 K⁺ channel autoantibodies increase IKs current and are associated with QT interval shortening in dilated cardiomyopathy. Cardiovasc Res. 1;98(3):496-503.

Schmidt C*, Wiedmann F*, Schweizer PA, Becker R, Katus HA, Thomas D (2012) Novel electrophysiological properties of dronedarone: Inhibition of human cardiac two-pore-domain potassium (K2P) channels. Naunyn Schmiedebergs Arch Pharmacol 385: 1003-16.

Schmidt C, Wiedmann F, Schweizer PA, Katus HA, Thomas D (2012) Kardiale Zwei-Porendomänen Kaliumkanäle (K2P): Physiologie, Pharmakologie und therapeutisches Potential. Dtsch Med Wochenschr 137: 1654-8.

Schmidt C, Kisselbach J, Schweizer PA, Katus HA, Thomas D. (2011) The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation. Vasc Health Risk Manag. 7:193-202.